%0 Journal Article
%T Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial
%A Akira Shimane
%A Hideo Tsubata
%A Hiroya Kawai
%A Kiminobu Yokoi
%A Kosuke Aoki
%A Michinori Takabe
%A Mitsuhiro Yokoyama
%A Naoko Hashimoto
%A Shogo Oishi
%A Soichiro Yamashita
%A Taishi Miyata
%A Takahiro Sawada
%A Takeshi Ohara
%A Tetsuari Onishi
%A Tsuyoshi Osue
%A Yasue Tsukishiro
%A Yasuyo Taniguchi
%A Yoshinori Yasaka
%J Archive of "Cardiovascular Diabetology".
%D 2016
%R 10.1186/s12933-016-0437-y
%X Recent experimental studies have revealed that n-3 fatty acids, such as eicosapentaenoic acid (EPA) regulate postprandial insulin secretion, and correct postprandial glucose and lipid abnormalities. However, the effects of 6-month EPA treatment on postprandial hyperglycemia and hyperlipidemia, insulin secretion, and concomitant endothelial dysfunction remain unknown in patients with impaired glucose metabolism (IGM) and coronary artery disease (CAD)
%K Eicosapentaenoic acid
%K Impaired glucose metabolism
%K Postprandial hyperglycemia
%K Postprandial insulin secretion
%K Postprandial hypertriglyceridemia
%K Endothelial dysfunction
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002116/